☆ 4.6 Article

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

Tien-Yi Lee et al.

Summary: Relugolix, a nonpeptide gonadotropin-releasing hormone receptor antagonist, is approved for the treatment of advanced prostate cancer. The recommended dosage is a loading dose of 360 mg followed by a daily dose of 120 mg. Population pharmacokinetic (PopPK) and pharmacokinetic/pharmacodynamic (PopPK/PD) models were developed using data from clinical studies to characterize relugolix exposure and its relationship to testosterone concentrations. The models showed that the recommended dosing regimen achieved castration levels of testosterone within a few days and maintained them even during temporary interruption of treatment.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Oncology

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

Saro Kasparian et al.

Summary: This study retrospectively reviewed the medical records of patients prescribed Relugolix for prostate cancer from January 1, 2021 to January 31, 2022. The results showed that 78% of the patients filled the prescription and had good medication compliance. The most common reason for not filling the prescription was the high cost of the medication. The study also found that there were no unexpected side effects when Relugolix was used in combination with other standard prostate cancer therapies.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion

Daniel Gorovets et al.

Summary: This study aimed to determine whether the presence of a PI-RADS 4 or 5 dominant intra-prostatic lesion (DIL) identified on pre-treatment multi-parametric magnetic resonance imaging (MRI) is associated with and more common within local recurrences after prostate stereotactic body radiation therapy (SBRT). The results suggest that patients with PI-RADS 4 or 5 DILs have a higher risk of local recurrence after SBRT, and most recurrences occur within the DIL.

EUROPEAN UROLOGY ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

Amar U. Kishan et al.

Summary: This individual patient data meta-analysis demonstrates that combining androgen deprivation therapy (ADT) with radiotherapy and prolonging the duration of ADT treatment after radiotherapy can significantly improve metastasis-free survival in men with localized prostate cancer, while neoadjuvant ADT extension does not have a similar effect.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Patient participation in treatment decision-making of prostate cancer: a qualitative study

Shucheng Pan et al.

Summary: This study aimed to explore patients' experiences and perceptions towards treatment decision-making. The findings revealed that patients with prostate cancer had varying degrees of involvement in the decision-making process, emphasizing their right to be informed about the disease condition and treatment options, as well as the importance of future considerations and advance care planning.

SUPPORTIVE CARE IN CANCER (2022)

添加到收藏夹

Article Urology & Nephrology

High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium

Amar U. Kishan et al.

Summary: This study compared the relative benefits of radiotherapy (RT) dose escalation with or without short-term or long-term androgen deprivation therapy (STADT or LTADT) in the treatment of prostate cancer through a network meta-analysis. The results showed that the addition of LTADT to RT had the greatest improvement in outcomes, followed by the addition of STADT. RT dose escalation did not improve metastasis-free survival (MFS), but had a high probability of improving biochemical recurrence-free survival (BCRFS) when used in conjunction with androgen deprivation therapy (ADT).

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Tamir N. Sholklapper et al.

Summary: In patients with localized prostate cancer, 5-fraction SBRT offers comparable oncologic outcomes and improved treatment compliance. However, despite the low FT associated with SBRT, significant socioeconomic disparities in FT remain.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

Ritchell van Dams et al.

Summary: The study aimed to investigate the efficacy and toxicity of stereotactic body radiation therapy in high-risk prostate cancer. The results showed a favorable toxicity and efficacy profile for SBRT in HRPCa patients.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study

Irving Kaplan et al.

Summary: Combining enzalutamide monotherapy with radiation therapy is effective for intermediate-risk prostate cancer, with high PSA response rates and fewer side effects, predominantly hypertension and gynecomastia.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Review Oncology

Androgen deprivation therapy and cardiovascular disease

Chiara Melloni et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)

添加到收藏夹

Article Urology & Nephrology

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

David P. Dearnaley et al.

EUROPEAN UROLOGY (2020)

添加到收藏夹

Editorial Material Urology & Nephrology

Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer

Sean Sachdev et al.

EUROPEAN UROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Neal D. Shore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Nursing

The fear of needles: A systematic review and meta-analysis

Jennifer McLenon et al.

JOURNAL OF ADVANCED NURSING (2019)

添加到收藏夹

Article Oncology

Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer

Johanna Wassermann et al.

CANCER (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Relugolix: First Global Approval

Anthony Markham

DRUGS (2019)

添加到收藏夹

Article Urology & Nephrology

Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer

Bruno Nascimento et al.

JOURNAL OF SEXUAL MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

Amar U. Kishan et al.

JAMA NETWORK OPEN (2019)

添加到收藏夹

Article Oncology

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation

Fady B. Geara et al.

RADIATION ONCOLOGY (2017)

添加到收藏夹

Letter Oncology

Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate-and High-Risk Prostate Cancer Reply

Aaron D. Falchook et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy A Secondary Analysis of a Randomized Clinical Trial

Trevor J. Royce et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males

David B. MacLean et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)

添加到收藏夹

Article Oncology

Impact of Neoadjuvant Prostate-Specific Antigen Kinetics on Biochemical Failure and Prostate Cancer Mortality: Results From a Prospective Patient Database

Marcus Foo et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)

添加到收藏夹

Article Oncology

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Leonard N. Chen et al.

RADIATION ONCOLOGY (2013)

添加到收藏夹

Article Urology & Nephrology

Testosterone in prostate cancer: the Bethesda consensus

Bob Djavan et al.

BJU INTERNATIONAL (2012)

添加到收藏夹

Review Urology & Nephrology

Gonadotropin-releasing hormone: An update review of the antagonists versus agonists

Hein Van Poppel et al.

INTERNATIONAL JOURNAL OF UROLOGY (2012)

添加到收藏夹

Article Oncology

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

Anthony V. D'Amico et al.

LANCET ONCOLOGY (2012)

添加到收藏夹

Article Oncology

EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER: URINARY OUTCOMES FOR MEN WITH HIGH INTERNATIONAL PROSTATE SYMPTOM SCORES (IPSS)

Renuka Malik et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

添加到收藏夹

Article Oncology

A COMPARISON OF THE PROGNOSTIC VALUE OF EARLY PSA TEST-BASED VARIABLES FOLLOWING EXTERNAL BEAM RADIOTHERAPY, WITH OR WITHOUT PRECEDING ANDROGEN DEPRIVATION: ANALYSIS OF DATA FROM THE TROG 96.01 RANDOMIZED TRIAL

David S. Lamb et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

添加到收藏夹

Article Oncology

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

James W. Denham et al.

LANCET ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

Dawn L. Hershman et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial

Anthony V. D'Amico et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)

添加到收藏夹

Article Oncology

Failure to achieve a PSA level ≤1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy

Darren M. Mitchell et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)

添加到收藏夹

Review Endocrinology & Metabolism

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

F Labrie et al.

ENDOCRINE REVIEWS (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.